Lisco Research Group

Primary and acquired immunodeficiencies like HIV/AIDS are associated with high prevalence of skin and mucosal diseases caused by Human Papillomaviruses (HPV) as well as an accelerated progression to HPV-related cancers. Dr. Lisco`s primary focus is on delineating the genetic, immunological, and molecular determinants of persistence, regression, or progression of HPV-related diseases to inform innovative preventive and therapeutic strategies. The translational workflow of the laboratory is based on the integration of clinical protocols focused on the identification of clinical and epidemiological predictors of severe HPV-related diseases with studies on host genetics and tissue-specific immunopathogenesis at the skin and mucosal barriers eventually informing personalized interventional clinical protocols.

Andrea Lisco, M.D., Ph.D (He/Him/His)

Assistant Clinical Investigator

Contact: For contact information, search the NIH Enterprise Directory.


M.D., University of Bari, Italy

Ph.D., University of Padua, Italy

Dr. Lisco earned his medical degree at University of Bari, Italy and pursued his research interests in viral immunology and pathogenesis of oncogenic viruses during his Ph.D. at the University of Padua, Italy and post-doctoral fellowship at the National Institutes of Health.

Learn more about Andrea Lisco, M.D., Ph.D

Andrea Lisco, M.D., Ph.D

Peiying Ye, Ph.D.


Contact: For contact information, search the NIH Enterprise Directory.

Languages Spoken: Chinese

Mapping the host determinants of HPV-related diseases in immunocompromised hosts (EPIC). Development of novel preventive and therapeutic strategies for severe HPV-related disease (NEPTUNE).

Learn more about Peiying Ye, Ph.D.

Peiying Ye, Ph.D., Biologist
Content last reviewed on